Condition: B-Cell Non-Hodgkin Lymphoma (NHL) · Richter's Transformation · T-Cell Non-Hodgkin Lymphoma · Sponsor: University of Pennsylvania
This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.
This description comes directly from the study's public registry record.
Abramson Cancer Center Clinical Trials Service · 215-349-8245 · PMCancerResearch@Pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07451054